CT检查时应用的对比药物是十分安全的

根据一项最新研究报道，已经在全球超过7千万患者中使用的对比药物碘普罗胺，无论其所需剂量或者体积，都能够用于各种形式的计算机X线断层扫描影像检查。

在该项研究中，来自位于波士顿的Brigham和妇女医院以及哈佛医学院的科学家，评估了29508例出于各种原因接受碘普罗胺对比增强CT检查的患者。在评估的患者中，有29297例并没有因为使用对比增强剂而出现副作用。在211例出现不良反应的患者中，只有4例被定级为严重反应。该研究发表在2005年1月《美国X线放射性期刊》上。

根据这些科学家的说法，碘普罗胺或者动脉内或者静脉内注射给药，在美国已经应用了大约10年之久，但是直到现在，该药只在按照特定剂量在某些特定检查比如血管造影、腹部CT中明确了其安全性。

这篇论文的主要作者Koenraad J. Mortele医生说：“我们开展这项研究的目的是阐明静脉使用对比增强药物的某些尚未被解决的问题，并在更大规模的患者中研究药物的安全性。我们相信这项研究为这种特定药物在大规模患者中的安全性提供了信息，并试图对CT对比增强药物的那些尚未解决的问题提供了答案。”

Common Contrast Agent Safe for CT Use
 
The contrast medium iopromide, which has been used on more than 70 million patients worldwide, can be used for all kinds of computed tomography (CT) imaging, regardless of the dosage or volume needed, according to a new study.

In the study, scientists from Brigham and Women’s Hospital and Harvard Medical School, both in Boston (MA, USA), assessed 29,508 patients who underwent contrast-enhanced CT with iopromide for a range of diagnostic reasons. Out of the patients examined, 29,297 suffered no unfavorable side effects due to the contrast agent utilized. Of the 211 who had adverse effects, only four were rated as severe. The study was published in the January 2005 issue of the American Journal of Roentgenology.

According to the scientists, iopromide has been available in the United States for approximately 10 years and can be administered either intra-arterially or intravenously, but until now its safety has only been established for certain procedures such as angiography and abdominal CT and only at specific dosage amounts.

“We undertook the study to clarify some unresolved questions about intravenous contrast agents and to have a benchmark study regarding the safety of the agent in a large group of patients,” said Koenraad J. Mortele, M.D., lead author of the article. “We believe this study provides insight into the safety of this specific contrast in a large group of patients and attempts to answer some of those unresolved questions regarding CT contrast agents,” added Dr. Mortele.